Dunphy C H
Department of Pathology, St Louis University Health Sciences Center, Missouri 63104, USA.
Am J Clin Pathol. 1998 May;109(5):625-30. doi: 10.1093/ajcp/109.5.625.
For this study, 188 bone marrow core biopsy specimens and aspirates analyzed morphologically and by flow cytometric immunophenotyping (FCI) in patients with a previous or new diagnosis of B-cell non-Hodgkin's lymphoma or mature B-cell leukemia were retrospectively reviewed to evaluate patterns of involvement and the usefulness of FCI. The morphologic and FCI results were categorized as follows: positive by morphologic examination and by FCI (39.9%); negative by morphologic examination and by FCI (41.5%); positive by morphologic examination and negative by FCI (11.7%); negative by morphologic examination and positive by FCI (2.6%); suggestive of malignant neoplasm by morphologic examination and positive by FCI (2.1%); and suggestive of malignant neoplasm by morphologic examination and negative by FCI (2.1%). Thus, in 81.4% of cases the morphologic and FCI findings were completely concordant. In 11.7% of cases, the morphologic examination alone detected involvement, and in 4.7% of cases, the FCI data detected involvement in a morphologically negative or "suggestive" bone marrow core. Combining these modalities is essential to evaluate bone marrow specimens for involvement by B-cell non-Hodgkin's lymphoma or B-cell leukemia.
在本研究中，我们回顾性分析了188例曾被诊断为B细胞非霍奇金淋巴瘤或成熟B细胞白血病，或新确诊此类疾病的患者的骨髓活检标本及穿刺物，通过形态学检查和流式细胞免疫表型分析（FCI）来评估受累模式及FCI的实用性。形态学和FCI结果分类如下：形态学检查和FCI均为阳性（39.9%）；形态学检查和FCI均为阴性（41.5%）；形态学检查为阳性而FCI为阴性（11.7%）；形态学检查为阴性而FCI为阳性（2.6%）；形态学检查提示为恶性肿瘤且FCI为阳性（2.1%）；形态学检查提示为恶性肿瘤且FCI为阴性（2.1%）。因此，在81.4%的病例中，形态学和FCI结果完全一致。在11.7%的病例中，仅形态学检查发现有受累情况，而在4.7%的病例中，FCI数据在形态学检查为阴性或“疑似”的骨髓活检中检测到受累情况。联合使用这些方法对于评估B细胞非霍奇金淋巴瘤或B细胞白血病累及的骨髓标本至关重要。
